Journal article

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: A systematic critical reappraisal

M Álvarez-Jiménez, C González-Blanch, B Crespo-Facorro, S Hetrick, JM Rodríguez-Sánchez, R Pérez-Iglesias, JL Vázquez-Barquero

CNS Drugs | Published : 2008

Abstract

Antipsychotic-induced weight gain is an important issue in the treatment of psychotic illnesses, and affects 80% of individuals being treated with antipsychotic drugs. However, the true dimension of weight gain and many accepted 'facts' in this area remain unclear as most research has been conducted in short-term trials and has included individuals receiving prolonged antipsychotic treatment. This review aims to systematically and critically review the evidence on weight gain induced by the two leading second-generation antipsychotics (olanzapine and risperidone) and the most widely researched first-generation antipsychotic (haloperidol) in patients with chronic and first-episode psychotic d..

View full abstract

Citation metrics